How were Nemus Bioscience's earnings last quarter?

Nemus Bioscience Inc (OTCMKTS:NMUS) announced its quarterly earnings data on Tuesday, May, 15th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter.

What other stocks do shareholders of Nemus Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nemus Bioscience investors own include Emerald Health Therapeutics (EMHTF) , KushCo (KSHB) , MedMen Enterprises (MMNFF) , Aurora Cannabis (ACBFF) , CannaRoyalty (ORHOF) , Unrivaled Brands (TRTC) , BOTS (MCIG) and Cronos Group (CRON) .

How do I buy shares of Nemus Bioscience?

Shares of NMUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:NMUS

Nemus Bioscience (NMUS) Stock Price, News & Analysis

→ With the “Bitcoin Loophole” you can supercharge the gains by 10x or more (From DTI) (Ad)

Free NMUS Stock Alerts

Compare

Today's Range: N/A
50-Day Range: $3.69
▼
$17.75
52-Week Range: N/A

Volume: 1.00 million shs
Average Volume: 377,395 shs
Market Capitalization: $87.04 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Nemus Bioscience alerts:

Ad The Bull Report

Healthcare Takes A Big Step Forward With The Help Of AI

The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.

Click here to see why this small company is trusted by the Mayo Clinic

About Nemus Bioscience Stock (OTCMKTS:NMUS)

Nemus Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics. The company's product candidates in preclinical stage include NB1111 for the treatment of glaucoma; NB1222 used for treating chemotherapy induced nausea and vomiting; and NB3111 for the treatment of methicillin-resistant staphylococcus aureus. Its products under research comprise NB2111 for use in treating chemotherapy induced peripheral neuropathy; and NB2222 for the treatment of uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy. Nemus Bioscience, Inc. has a license agreement with the University of Mississippi to research, develop, and commercialize products for the treatment of infectious diseases. The company was founded in 2012 and is headquartered in Costa Mesa, California.

Ad Darwin

2024's Must-Have Guide: Master Crypto Investment Today

The cryptocurrency revolution is here with Bitcoin soaring past the $70,000 milestone—a clear indicator of the booming digital currency market. Are you prepared to navigate these exciting yet complex waters? Introducing "Navigating the Future: A Comprehensive Guide to Cryptocurrency Investments in 2024." This free digital guide is your essential resource for understanding and capitalizing on cryptocurrency investments, tailored for both newcomers and seasoned investors. (**By clicking the link you are subscribing to The Conservative Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

Click here to download your crypto report

NMUS Stock News Headlines

March 16, 2024 | morningstar.com

Assembly Biosciences Inc ASMB

September 5, 2023 | money.usnews.com

Sagimet Biosciences Inc - Ordinary Shares - Class A

April 18, 2024 | DTI (Ad)

This company has increased its dividend every year for 54 years

There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.

April 27, 2023 | finance.yahoo.com

Satellos Bioscience Announces Closing of Previously Announced Non-Brokered Offering of $2.385 Million of Unsecured Non-Convertible Debentures

April 6, 2023 | finanznachrichten.de

Crown Bioscience Announces Transaction Closing of Indivumed's Service Business and Supporting Biobank

February 24, 2023 | finance.yahoo.com

Psycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD

January 27, 2023 | finance.yahoo.com

SN BioScience and Boryung Announce the Licensing Agreement on Generic Version of Abraxane

January 27, 2023 | yahoo.com

Crown Bioscience to Acquire Indivumed’s Service Business and Supporting Biobank

April 18, 2024 | DTI (Ad)

This company has increased its dividend every year for 54 years

January 27, 2023 | finance.yahoo.com

Renaissance BioScience Corp. and Timeless Capital Corp. Enter into Letter of Intent

October 26, 2022 | finance.yahoo.com

BioScience Managers Announces the Appointment of Dr. David Atkins as Managing Partner to Continue its Growth in Digital Health

September 23, 2022 | finance.yahoo.com

Neurocrine Biosciences, Inc. (NBIX)

See More Headlines

Receive NMUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nemus Bioscience and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/15/2018
Today: 4/18/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: N/A
Sub-Industry: Cannabis
Current Symbol: OTCMKTS:NMUS
CUSIP: N/A
CIK: N/A
Web: www.nemusbioscience.com
Phone: 949-396-0330
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-19,190,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -924.42%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.12
Quick Ratio: 0.12

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.12) per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 133,908,000
Free Float: N/A
Market Cap: $87.04 million
Optionable: Not Optionable
Beta: -0.04

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Dr. Brian S. Murphy (Age 61)
CEO, Chief Medical Officer & Director
Dr. Avtar S. Dhillon (Age 57)
Exec. Chairman
Mr. Douglas A. Cesario (Age 44)
Chief Financial Officer
Ms. Wendy Cunning
VP of Bus. Operations

Key Competitors

View All Competitors

NMUS Stock Analysis - Frequently Asked Questions

How were Nemus Bioscience's earnings last quarter?: Nemus Bioscience Inc (OTCMKTS:NMUS) announced its quarterly earnings data on Tuesday, May, 15th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter.
What other stocks do shareholders of Nemus Bioscience own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Nemus Bioscience investors own include Emerald Health Therapeutics (EMHTF), KushCo (KSHB), MedMen Enterprises (MMNFF), Aurora Cannabis (ACBFF), CannaRoyalty (ORHOF), Unrivaled Brands (TRTC), BOTS (MCIG) and Cronos Group (CRON).
How do I buy shares of Nemus Bioscience?: Shares of NMUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:NMUS) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial